Core Viewpoint - On December 22, the company announced a licensing agreement with Ipsen for the global development, production, and commercialization rights of the antibody-drug conjugate SIM0613, targeting LRRC15, outside Greater China, with potential payments up to $1.06 billion [1] Group 1: Agreement Details - The agreement includes an upfront payment of $45 million, along with milestone payments related to research, regulatory, and commercialization phases [1] - The company is entitled to receive tiered royalties on sales of SIM0613 [1] Group 2: Product Information - SIM0613 is a novel ADC that targets LRRC15, which is highly expressed on the surface of various solid tumors and cancer-associated fibroblasts (CAFs), but minimally expressed in normal cells [1] - Upon binding to LRRC15, SIM0613 enters tumor cells through endocytosis, releasing a cytotoxic payload that kills tumor cells while sparing normal cells [1] - The design of SIM0613 allows for deep penetration into tumors and CAFs, demonstrating significant tumor regression effects in various preclinical in vivo models [1]
先声药业：与益普生（Ipsen）就SIM0613（LRRC15抗体偶联药物）签订独家授权许可协议